NMRA welcomes your comments and feedback on the proposed Guideline for monitoring and reporting Adverse Drug Reactions.This will start from 1st of October 2019 & end 15th October 2019.

Please provide your name, the organization you represent, mailing address and contact number to follow up with you to clarify any issue if necessary.

Please email your feedback to This email address is being protected from spambots. You need JavaScript enabled to view it. by 15th October 2019.

Guideline for monitoring and reporting Adverse Drug Reaction